Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.39 |
| ▸ | GCGR | P47871 | 2/20 | 0.37 |
| ▸ | GIPR | P48546 | 2/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | WNT3A | P56704 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2859562 | 0.88 | MAPT (0.34) | MAPTDYRK1ACYP3A4WNT3ACSNK1D | |
| SCHEMBL2867706 | 0.86 | EPHX2 (0.42) | MAPTEPHX2DYRK1AFLT1KDR | |
| SCHEMBL2870252 | 0.85 | EPHX2 (0.45) | MAPTEPHX2DYRK1ACSNK1D | |
| SCHEMBL2864054 | 0.85 | MAPT (0.44) | MAPTEPHX2CYP3A4WNT3A | |
| SCHEMBL2868215 | 0.84 | EPHX2 (0.42) | MAPTEPHX2GCGRGIPRGLP1R | |
| SCHEMBL2863564 | 0.82 | EPHX2 (0.42) | MAPTEPHX2 | |
| SCHEMBL2867284 | 0.82 | MAPT (0.41) | MAPTEPHX2DYRK1AKDRCSNK1D | |
| SCHEMBL2663180 | 0.81 | GCGR (0.47) | EPHX2GCGRGIPRGLP1RDYRK1A | |
| SCHEMBL2860311 | 0.81 | EPHX2 (0.41) | MAPTEPHX2DYRK1A | |
| SCHEMBL2859768 | 0.80 | CA1 (0.45) | MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370260-B1 | AZOLES AS MALONYL-COA DECARBOXYLASE INHIBITORS USEFUL AS METABOLIC MODULATORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2010-11-24 | — | — | EP | claimed |
| US-7709510-B2 | Azoles as malonyl-CoA decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-04 | — | — | US | claimed |
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092503-A1 | Azoles as malonyl-coa decarboxylase inhibitors useful as metabolic modulators | ME1, ME3, ME2 | MAPT 3030/4885EPHX2 1552/4885GCGR 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.